Selectin ligands

Selectin ligands are a diverse group of cell-surface glycoconjugates, including glycoproteins and glycolipids, that facilitate the initial adhesion of leukocytes and tumor cells to the vascular endothelium. The most prominent ligands, such as P-selectin glycoprotein ligand-1 (PSGL-1), Sialyl-Lewis X (sLeX), and Sialyl-Lewis A (sLeA), are characterized by specific sialylated and fucosylated carbohydrate motifs recognized by the selectin family of adhesion molecules (E-, P-, and L-selectin). This interaction mediates the "tethering and rolling" of cells along the vessel wall, a critical first step in leukocyte extravasation during inflammation and the metastatic spread of cancer cells. In the tumor microenvironment, the overexpression of selectin ligands on cancer cells and the activation of selectins on the tumor endothelium promote the recruitment of inflammatory cells and the survival of circulating tumor cells. Therapeutic targeting of these ligands, either through direct monoclonal antibodies or by using selectin inhibitors that block ligand binding sites, aims to disrupt these pathological interactions to treat inflammatory disorders and prevent cancer progression.

Other names

P-selectin glycoprotein ligand-1 (PSGL-1)Sialyl-Lewis X (sLeX)Sialyl-Lewis A (sLeA)CD162HCELL (Hematopoietic Cell E-/L-selectin Ligand)ESL-1 (E-selectin ligand-1)CD34GlyCAM-1MAdCAM-1Cutaneous lymphocyte-associated antigen (CLA)

Competitive inhibition of selectin-ligand binding; blockade of leukocyte and tumor cell tethering and rolling on the vascular endothelium; inhibition of cell extravasation and recruitment to inflammatory or metastatic sites.